Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment - PubMed (original) (raw)

Review

Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment

Jens Pahnke et al. Neurobiol Dis. 2014 Dec.

Abstract

Much has been said about the increasing number of demented patients and the main risk factor 'age'. Frustratingly, we do not know the precise pattern and all modulating factors that provoke the pathologic changes in the brains of affected elderly. We have to diagnose early to be able to stop the progression of diseases that irreversibly destroy brain substance. Familiar AD cases have mislead some researchers for almost 20 years, which has unfortunately narrowed the scientific understanding and has, thus, lead to insufficient funding of independent approaches. Therefore, basic researchers hardly have been able to develop causative treatments and clinicians still do not have access to prognostic and early diagnostic tools. During the recent years it became clear that insufficient Aβ export, physiologically facilitated by the ABC transporter superfamily at the brain's barriers, plays a fundamental role in disease initiation and progression. Furthermore, export mechanisms that are deficient in affected elderly are new targets for activation and, thus, treatment, but ideally also for prevention. In sporadic AD disturbed clearance of β-amyloid from the brain is so far the most important factor for its accumulation in the parenchyma and vessel walls. Here, we review findings about the contribution of ABC transporters and of the perivascular drainage/glymphatic system on β-amyloid clearance. We highlight their potential value for innovative early diagnostics using PET and describe recently described, effective ABC transporter-targeting agents as potential causative treatment for neurodegenerative proteopathies/dementias.

Keywords: ABC transporter; ABCA7; ABCB1; ABCC1; Alzheimer’s disease; Amyloid-beta; BBB; Blood–brain barrier; Choroid plexus; Glymphatic system; Neurodegeneration; PET.

Copyright © 2014 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Abe-Dohmae S, et al. Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J Biol Chem. 2004;279:604–11. - PubMed
    1. Baello S, et al. TGF-beta1 regulation of multidrug resistance P-glycoprotein in the developing male blood-brain barrier. Endocrinology. 2014;155:475–84. - PubMed
    1. Bartels AL, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm. 2008;115:1001–9. - PMC - PubMed
    1. Bateman RJ, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856–61. - PMC - PubMed
    1. Bauer B, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol. 2008;73:1444–53. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources